The NCCN breast cancer clinical practice guidelines recommended that Alpelisib plus fulvestrant combination therapy should be used as the first choice for the treatment of HR + /HER2- breast cancer patients carrying PIK3CA mutations. This evidence concerns the gene PIK3CA and breast cancer.